A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 11 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ori CAR 017 (Primary) ; Cyclophosphamide; Fludarabine; Steroids; Tocilizumab
Indications Multiple myeloma
Focus Adverse reactions; First in man
Acronyms Oricar-017; POLARIS

05 Jun 2024 Results presented in the OriCell Therapeutics Media Release.
05 Jun 2024 According to an OriCell Therapeutics media release, long term data from this trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
04 Jun 2024 Results (At data cut-off (Jan 16, 2024)presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com